Factors Associated with Dose Determination of Radioactive Iodine Therapy for Differentiated Thyroid Cancer

被引：13
作者：
Hong C.M. [1 ,2 ]
Ahn B.-C. [1 ,2 ]
机构：
[1] Department of Nuclear Medicine, School of Medicine, Kyungpook National University, 680, Gukchaebosang-ro, Jung-gu, Daegu
[2] Department of Nuclear Medicine, Kyungpook National University Hospital, 130 Dongdeok-ro, Jung-gu, Daegu
来源：
Nuclear Medicine and Molecular Imaging | 2018年 / 52卷 / 4期
基金：
新加坡国家研究基金会;
关键词：
Differentiated thyroid cancer; High dose; I-131; Low dose; Radioactive iodine;
D O I：
10.1007/s13139-018-0522-0
中图分类号：
学科分类号：
摘要：
Radioactive iodine (RAI) therapy for differentiated thyroid cancer has been successfully used for more than 70 years. However, there is still plenty of controversy surrounding the use and doses of radioiodine. There is insufficient evidence to answer the questions. Recent American Thyroid Association (ATA) guidelines seem to favor low-dose RAI, based on recent clinical trials and meta-analyses. However, long-term follow-up data remains limited, and there are additional factors we should consider that might affect the efficacy of RAI therapy. Therefore, until sufficient data are available, it is necessary to remain cautious about determining RAI doses by considering multiple patient-specific variables. © 2018, Korean Society of Nuclear Medicine.
引用
收藏
页码：247 / 253
页数：6
相关论文
共 72 条
  • [1] La Vecchia C., Malvezzi M., Bosetti C., Garavello W., Bertuccio P., Levi F., Et al., Thyroid cancer mortality and incidence: a global overview, Int J Cancer, 136, pp. 2187-2195, (2015)
  • [2] Verburg F.A., Mader U., Reiners C., Hanscheid H., Long-term survival in differentiated thyroid cancer is worse after low-activity initial post-surgical 131I therapy in both high- and low-risk patients, J Clin Endocrinol Metab, 99, pp. 4487-4496, (2014)
  • [3] Hong C.M., Ahn B.-C., Redifferentiation of radioiodine refractory differentiated thyroid cancer for reapplication of I-131 therapy, Front Endocrinol, 8, (2017)
  • [4] Verburg F.A., Hanscheid H., Luster M., Radioactive iodine (RAI) therapy for metastatic differentiated thyroid cancer, Best Pract Res Clin Endocrinol Metab, 31, pp. 279-290, (2017)
  • [5] Haugen B.R., Alexander E.K., Bible K.C., Doherty G.M., Mandel S.J., Nikiforov Y.E., Et al., 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid Cancer, Thyroid, 26, pp. 1-133, (2016)
  • [6] Jeong J.H., Kong E.J., Jeong S.Y., Lee S.-W., Cho I.H., Ah Chun K., Et al., Clinical outcomes of low-dose and high-dose postoperative radioiodine therapy in patients with intermediate-risk differentiated thyroid cancer, Nucl Med Commun, 38, pp. 228-233, (2017)
  • [7] Yi K.H., Lee E.K., Kang H.-C., Koh Y., Kim S.W., Kim I.J., Et al., 2016 revised Korean thyroid association management guidelines for patients with thyroid nodules and thyroid cancer, Int J Thyroidol, 9, (2016)
  • [8] National Comprehensive Cancer Network Clinical Practice Guideline in Oncology Guideline (NCCN Guidelines) Thyroid Carcinoma, (2017)
  • [9] Hong C.M., Ahn B.-C., Park J.Y., Jeong S.Y., Lee S.-W., Lee J., Prognostic implications of microscopic involvement of surgical resection margin in patients with differentiated papillary thyroid cancer after high-dose radioactive iodine ablation, Ann Nucl Med, 26, pp. 311-318, (2012)
  • [10] Mallick U., Harmer C., Yap B., Wadsley J., Clarke S., Moss L., Et al., Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer, N Engl J Med, 366, pp. 1674-1685, (2012)
12345678